SPECTRA SCIENCE

2515 McKinney Avenue, Suite 1000, Dallas, TX 75201, United States All United States companies → — Founded 2009

Imaging AI Specialist Medical Device / Hardware Point-of-Care Diagnostics

OB/GYN AI Oncology AI Radiology & Imaging AI

Publicly Traded (Nasdaq: MDAI) — Spectral AI has secured significant funding, including a contract with the Biomedical Advanced Research and Development Authority (BARDA) valued up to $150.0 million, with $86.6 million committed to date. Additionally, the company completed a debt financing agreement of up to $15.0 million in March 2025, with an initial draw of $8.5 million, alongside $2.7 million in equity financing. In October 2025, they also announced a $7.6 million offering.

Claim this company

Products

LUMA CERVICAL IMAGING SYSTEM

SPECTRA SCIENCE

OB/GYN AI

A non-invasive optical imaging system by SpectraScience that enhances colposcopy for the improved detection of high-grade pre-cancerous cervical lesions using fluorescence and reflectance spectroscopy.

See all 1 product →

About SPECTRA SCIENCE

Spectral AI is an artificial intelligence company specializing in medical diagnostics and predictive analytics for advanced wound care. Their flagship product, the DeepView® System, leverages proprietary AI algorithms combined with multispectral imaging technology to provide clinicians with objective, immediate assessments of a wound’s healing potential. This innovative approach aims to “See the Unknown®” by detecting subtle tissue characteristics that are invisible to the human eye, thereby facilitating faster and more accurate treatment decisions. The technology is primarily focused on applications for burn wound assessment and diabetic foot ulcers (DFUs).

For physicians, the DeepView System offers a non-invasive, non-radiation, and non-laser method to differentiate between fully damaged, partially damaged, and healthy human tissue at the initial presentation of a wound. This capability is critical for guiding optimal treatment strategies, particularly in high-stakes scenarios such as mass casualty burn incidents, where rapid and precise patient triage is essential for efficient resource allocation and surgical management. By providing a clear healing map of the wound before any interventions, Spectral AI’s technology is designed to significantly enhance the current standard of care, leading to improved patient outcomes and potentially reducing healthcare costs.

Focus Areas

Medical diagnostics predictive analytics wound care burn assessment diabetic foot ulcer assessment artificial intelligence multispectral imaging

Business Intelligence

Key Investors	Northland Capital Markets, Avenue Venture Opportunities Fund II, L.P., institutional and existing UK investors, YA II PN, Ltd. (Yorkville)
Partnerships	Biomedical Advanced Research and Development Authority (BARDA), Medical Technology Enterprise Consortium (MTEC), national leaders in burn care, clinical and academic partners in the United States and Europe
Acquisitions	Rosecliff Acquisition I (merged in 2023 to go public)
Technology	DeepView® System, proprietary AI algorithms, multispectral imaging (MSI)
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

Medical Diagnostics

Specializes in predictive wound healing diagnostics, offering objective and immediate assessments for acute and chronic wounds.

Predictive Analytics

Utilizes proprietary Artificial Intelligence (AI) to provide immediate wound healing predictions, offering insights not visible to the human eye.

Wound Care

Transforms wound care by providing clinicians with advanced tools for faster and more accurate treatment decisions, impacting patient outcomes and cost of care.

Burn Assessment

DeepViewu00ae system assesses burn healing potential and helps determine the depth of burn wounds, aiming to reduce incorrect assessments and improve early intervention.

Diabetic Foot Ulcer Assessment

Offers objective and immediate assessment of Diabetic Foot Ulcers (DFUs) healing potential, aiming to reduce infections, healing times, and the risk of amputation.

Artificial Intelligence

Combines AI with multispectral imaging technology to power its diagnostic platform, enabling data-driven predictions for wound healing.

Multispectral Imaging

Employs noninvasive multispectral imaging technology to capture detailed wound data, enhancing diagnostic accuracy and treatment planning.

Key Differentiators

Provides immediate, objective, and accurate wound healing predictions on Day One, moving beyond subjective clinical assessments. The unique combination of AI and multispectral imaging addresses critical challenges in managing complex wounds like burns and diabetic foot ulcers, potentially reducing waiting times, patient costs, and infection rates.

Technology Stack

The core technology is the DeepViewu00ae Wound Imaging System, a portable multimodal platform that integrates multispectral imaging with proprietary AI and machine-learning models to generate objective tissue assessments and predictive outputs.

Physician Tip

For physicians, Spectral AI's DeepViewu00ae system offers a significant advantage by providing objective, data-driven insights into wound healing potential from Day One. This can lead to earlier and more precise treatment decisions, potentially reducing complications, improving patient outcomes, and optimizing resource utilization. The technology aims to eliminate the 'wait and see' approach, particularly for challenging cases like diabetic foot ulcers and burns, by offering a clear healing map and predictive accuracy.

While the DeepViewu00ae system is a portable imaging platform with algorithmic assessment, specific details regarding its integration capabilities with existing Electronic Health Record (EHR) or other hospital information systems are not explicitly detailed in the provided information. However, such integration would typically be crucial for seamless workflow adoption and data management in clinical settings.

At a glance

Founded 2009

HQ 2515 McKinney Avenue, Suite 1000, Dallas, TX 75201, United States · United States

Team size 65

CEO Vincent S. Capone

Funding Publicly Traded (Nasdaq: MDAI) — Spectral AI has secured significant funding, including a contract with the Biomedical Advanced Research and Development Authority (BARDA) valued up to $150.0 million, with $86.6 million committed to date. Additionally, the company completed a debt financing agreement of up to $15.0 million in March 2025, with an initial draw of $8.5 million, alongside $2.7 million in equity financing. In October 2025, they also announced a $7.6 million offering.

FDA clearances 2 (estimated)

Products 1

Products by SPECTRA SCIENCE

1 product in the directory

LUMA CERVICAL IMAGING SYSTEM

SPECTRA SCIENCE

OB/GYN AI

Reviews & Opinions

No web reviews on file yet for SPECTRA SCIENCE. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about SPECTRA SCIENCE.

Loading videos...

Videos load interactively. If none appear, search YouTube for SPECTRA SCIENCE →

View all on YouTube

Press & Coverage

PR Newswire

Spectrum Science Expands Integrated Strategic Platform With Launch of Full-Service Media Offering

Spectrum Science announced the formalization of Spectrum Science Media, an omnichannel, performance media planning, buying, and optimization service with data integration and audience insights. The company is also developing an AI-powered evolution of its Galileo6 media analytics and modeling platform.

2025-05

PR Newswire

Spectrum Science Unifies Portfolio Companies Under Single Brand, Reinforcing Power of Integrated Strategic Platform

Spectrum Science announced the unification of its suite of brandsu2014Aurora, Continuum Clinical, CrowdPharm, and Hot Iron Healthu2014under the Spectrum Science name, effective December 2025. This move aims to amplify the clarity and strength of one unified brand for its integrated clinical, commercial, and communications services.

2025-12

PR Newswire

Spectrum Science Acquires Return on Focus, Expanding Strategic Capabilities to Drive Brand Success through Proprietary, Evidence-Based Approach to Positioning

Spectrum Science acquired Return on Focus, a strategic marketing organization specializing in evidence-based positioning for pharmaceutical and biotech companies. This acquisition is the third for Spectrum since its partnership with Knox Lane in 2023, strengthening its strategic and commercial offerings.

2025-09

PR Newswire

Spectrum Science Establishes Source, A Proprietary, AI-powered Platform Enabling Access to a Global Flex Force of Health and Life Science Industry Specialists

Spectrum Science launched Source, a proprietary, AI-powered platform designed to access a global flexible talent force of health and life science industry specialists. This platform aims to revolutionize agility and flexibility for clients needing maximum impact at a rapid pace.

2025-04

Wiley Analytical Science

Spectral urine analysis for non-invasive, rapid diagnosis

This article discusses how recent technological advancements in optical (spectral) methods are enabling rapid, accurate, and non-invasive diagnosis through urine analysis, offering a promising alternative to traditional biopsy methods. These techniques rely on capturing spectral signatures from urine molecules to reveal qualitative and quantitative information.

2025-08

PMC - NIH

Machine learning spectroscopy to advance computation and analysis

This review explores the synergy between machine learning and spectroscopy, highlighting how machine learning has revolutionized spectroscopy by enabling computationally efficient predictions, expanding synthetic data libraries, and facilitating high-throughput screening in diverse fields like biology, materials science, medicine, and chemistry.

2025-11

FDA

Spectra Therapy, LLC MARCS-CMS 698026 u2014 July 22, 2025

The FDA issued a warning letter to Spectra Therapy, LLC on July 22, 2025, following a September 2024 inspection that found violations of Quality System Regulation regarding their therapeutic heating infrared lamps (LASERwrap system). The firm was cited for manufacturing, packing, storage, or installation methods not conforming to good manufacturing practice requirements and for failing to submit required information to GUDID.

2025-07

U.S. Department of Energy

U.S. Department of Energy Invests $320 Million in Pioneering Scientific Research

The U.S. Department of Energy announced over $320 million in funding for 217 university and industry projects in physical sciences, including chemical and molecular sciences, quantum information science, and advanced sensors. These awards, totaling $320 million for projects up to 5 years, with $174 million in FY 2026 and prior year funding, aim to expand scientific knowledge and address critical technology needs.

2026-03

Frequently Asked Questions

How does Spectral AI's DeepViewu00ae technology enhance medical diagnostics for wound care, particularly for burns and diabetic foot ulcers?

Spectral AI's DeepViewu00ae technology combines multispectral imaging and artificial intelligence to provide objective, 'Day One' healing predictions for wounds. This system captures millions of data points invisible to the human eye, enabling earlier and more accurate assessment of tissue viability in burns and diabetic foot ulcers.

What is the role of predictive analytics and AI in DeepViewu00ae for assessing wound healing potential?

DeepViewu00ae utilizes AI algorithms trained on extensive clinical databases, including the world's largest burn biopsy tissue bank, to integrate multispectral image data with clinical information. This allows for an immediate, objective, and highly accurate binary prediction of a wound's healing potential, moving beyond subjective assessments.

What are the key clinical benefits of using DeepViewu00ae for burn and diabetic foot ulcer assessment compared to traditional methods?

DeepViewu00ae offers significantly higher accuracy in assessing burn depth and DFU healing potential compared to traditional subjective evaluations, which can be as low as 50-70% accurate even for experts. This leads to earlier, more appropriate treatment decisions, potentially reducing complications, hospital stays, and the risk of amputations.

What is the regulatory status of Spectral AI's DeepViewu00ae system, particularly with the FDA?

Spectral AI's DeepViewu00ae technology has received FDA Breakthrough Designation for burn assessment, indicating its potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. The company is also conducting multi-center studies to support regulatory applications for diabetic foot ulcers in the US, UK, and EU.

What kind of support and training does Spectral AI provide for integrating DeepViewu00ae into clinical practice?

Spectral AI is expected to offer comprehensive training programs for clinical staff on device operation and data interpretation to ensure effective use. Ongoing technical support and clinical education would also be provided to facilitate seamless integration and optimal utilization in diverse healthcare settings.

How does the cost of DeepViewu00ae compare to current assessment methods, and what is its potential for reimbursement?

Although specific pricing details are not publicly available, DeepViewu00ae aims to reduce overall healthcare costs by enabling earlier intervention, minimizing prolonged hospital stays, and preventing severe complications like amputations. These efficiencies, coupled with its diagnostic accuracy, could support favorable reimbursement pathways as a novel, impactful diagnostic tool.

What is the long-term vision for Spectral AI, and what future developments can physicians expect?

Spectral AI is committed to expanding its DeepViewu00ae platform beyond burns and DFUs to other wound care applications, such as venous leg ulcers and critical limb ischemia. The company continues to leverage its AI data pipeline and proprietary databases to develop innovative technologies like AI-3D wound measurement, indicating a strong focus on continuous innovation and growth.

Related Companies

Suggest an Edit →